Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
详细信息 查看全文
- 作者：Khanh Do ; Giovanna Speranza ; Rachel Bishop ; Sonny Khin…
- 关键词：MK ; 2206 ; Selumetinib ; pAKT ; pERK ; Colorectal carcinoma
- 刊名：Investigational New Drugs
- 出版年：2015
- 出版时间：June 2015
- 年：2015
- 卷：33
- 期：3
- 页码：720-728
- 全文大小：1,420 KB
- 参考文献：1.Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50(5):307鈥?12. doi:10.鈥?002/鈥媑cc.鈥?0854 View Article PubMed
2.Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011鈥?019. doi:10.鈥?200/鈥婮CO.鈥?010.鈥?3.鈥?091 View Article PubMed
3.Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23(1):201鈥?05View Article PubMed
4.Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72(13):3228鈥?237. doi:10.鈥?158/鈥?008-5472.鈥婥AN-11-3747 View Article PubMed Central PubMed
5.Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70(17):6804鈥?814. doi:10.鈥?158/鈥?008-5472.鈥婥AN-10-0409 View Article PubMed Central PubMed
6.Biondo A, Yap TA, Yan L, Patnaik A, Fearen I, Baird RD, Papadopoulos KP, Delgado LM, Taylor A, Lupinacci L, Blackman SC, Decordova S, Tall M, Heaton S, Garrett MD, Sullivan D, De Bono JS, Tolcher AW (2011) Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. J Clin Oncol 29(suppl):3037, abstract
7.Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688鈥?695. doi:10.鈥?200/鈥婮CO.鈥?011.鈥?5.鈥?263 View Article PubMed
8.Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209鈥?219. doi:10.鈥?158/鈥?535-7163.鈥婱CT-07-0231 View Article PubMed
9.Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS (2014) Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK. Clin Cancer Res. doi:10.鈥?158/鈥?078-0432.鈥婥CR-14-1901 PubMed Central
10.Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956鈥?967. doi:10.鈥?158/鈥?535-7163.鈥婱CT-09-1012 View Article PubMed
11.Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH (2010) The statistics of phase 0 trials. Stat Med 29(10):1072鈥?076. doi:10.鈥?002/鈥媠im.鈥?840 View Article PubMed Central PubMed
12.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228鈥?47. doi:10.鈥?016/鈥媕.鈥媏jca.鈥?008.鈥?0.鈥?26 View Article PubMed
13.Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26(13):2139鈥?146. doi:10.鈥?200/鈥婮CO.鈥?007.鈥?4.鈥?956 View Article PubMed Central PubMed
14.Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16(5):1613鈥?623. doi:10.鈥?158/鈥?078-0432.鈥婥CR-09-2483 View Article PubMed
15.Khan KH, Yan L, Mezynski J, Patnaik A, Moreno V, Papadopoulos KP, Garrett CR, Ong M, Shannon KA, Morosky A, Rubin EH, Tetteh E, Skolnik J, Smith IC, Smith PD, De Bono JS, Tolcher AW (2012) A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 30(suppl):e13599, abstract
16.Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K (2011) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47(13):1946鈥?954. doi:10.鈥?016/鈥媕.鈥媏jca.鈥?011.鈥?3.鈥?29 View Article PubMed
17.Ang JE, Kaye S, Banerji U (2012) Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr Drug Targets 13(12):1525鈥?534View Article PubMed Central PubMed - 作者单位：Khanh Do (1)
Giovanna Speranza (1)
Rachel Bishop (2)
Sonny Khin (3)
Larry Rubinstein (1)
Robert J. Kinders (3)
Manuel Datiles (2)
Michelle Eugeni (1)
Michael H. Lam (4)
L. Austin Doyle (1)
James H. Doroshow (1)
Shivaani Kummar (1)
1. Division of Cancer Treatment and Diagnosis, National Cancer Institute, 31 Center Drive, Bldg 31, Rm 3A44, Bethesda, MD, 20892, USA
2. National Eye Institute, Bethesda, USA
3. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, USA
4. Merck Research Laboratories 鈥?Oncology, Boston, USA - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology
Pharmacology and Toxicology - 出版者：Springer Netherlands
- ISSN：1573-0646
文摘